2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17406S
    Tolcapone-d7 98%
    Tolcapone-d7 is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.
    Tolcapone-d7
  • HY-17408R
    Mevastatin (Standard) 73573-88-3
    Mevastatin (Standard) is the analytical standard of Mevastatin. This product is intended for research and analytical applications. Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.
    Mevastatin (Standard)
  • HY-174127
    P2Y1 antagonist 3
    P2Y1 antagonist 3 (compound 36b) is a blood-brain barrier (BBB)-penetrant P2Y1 antagonist with an IC50 of 0.50 μM. P2Y1 antagonist 3 exhibits protective effects in a rat middle cerebral artery occlusion (MCAO) model and demonstrates neuroprotective activity against oxidative stress by upregulating nuclear Nrf2 protein levels.
    P2Y1 antagonist 3
  • HY-17412S
    Minocycline-d6 hydrochloride 1035979-33-9 98%
    Minocycline-d6 hydrochloride is deuterated labeled Minocycline hydrochloride (HY-17412). Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6 hydrochloride
  • HY-174146
    5-HT1A agonist 1 2410053-15-3
    5-HT1A agonist 1 (Compound Ex.37) is a highly selective 5-HT1a receptor agonist (EC50=0.18 nM). 5-HT1A agonist 1 mimicks serotonin binding to the receptor, promotes postsynaptic membrane hyperpolarization, inhibits neuronal hyperexcitability, and reduces the release of anxiety-related neurotransmitters. 5-HT1A agonist 1 is promising for research of neuropsychiatric diseases.
    5-HT1A agonist 1
  • HY-174147
    GABAB receptor antagonist 4 91981-93-0
    GABAB receptor antagonist 4 (Compound 28) is a GABAB receptor antagonist. GABAB receptor antagonist 4 can inhibit GABA-induced G protein activation. GABAB receptor antagonist 4 competitively binds to the orthosteric site of GABAB receptor. GABAB receptor antagonist 4 can be used to study GABAB receptor-related neurological diseases.
    GABAB receptor antagonist 4
  • HY-174152
    GABAB receptor antagonist 5
    GABAB receptor antagonist 5 (Compound 23) is a competitive GABAB receptor antagonist. GABAB receptor antagonist 5 is promising for research of neuropsychiatric diseases, such as epilepsy, depression, and addiction.
    GABAB receptor antagonist 5
  • HY-174153
    PSB-22219 1404529-43-6
    PSB-22219 is a highly selective non-nucleotidic ligand acting on P2Y12 receptors (KD=4.57 nM). PSB-22219 is promising for research of P2Y12 receptor-associated neuroinflammation.
    PSB-22219
  • HY-174155
    Sigma-2 Receptor ligand 1
    Sigma-2 Receptor ligand 1 (Compound 7i) is a highly selective Sigma-2 receptor ligand with a Ki value of 40 nM. Sigma-2 Receptor ligand 1 is promising for research of Alzheimer's disease.
    Sigma-2 Receptor ligand 1
  • HY-174157
    AR493 1290546-06-3
    AR493 is an autophagy activator acting on AMPK (adenosine monophosphate-activated protein kinase). AR493 regulates pathways related to cellular energy sensing and increases autophagy levels. AR493 is promising for research of aging-associated diseases (such as diabetes, neurodegenerative diseases) and autophagy regulation.
    AR493
  • HY-174229
    SM311
    SM311 (Compound 10) is a potent selective irreversible LIMK1 inhibitor (EC50=0.045 μM, >30-fold selective over LIMK2). SM311 blocks cofilin phosphorylation and actin cytoskeleton regulation. SM311 is promising for research of neurodegenerative diseases like Fragile X syndrome (FXS) and Alzheimer’s disease, as well as tumor invasion.
    SM311
  • HY-174272
    GSK-3β inhibitor 27
    GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC50 value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease).
    GSK-3β inhibitor 27
  • HY-17440R
    Rocuronium Bromide (Standard) 119302-91-9
    Rocuronium (Bromide) (Standard) is the analytical standard of Rocuronium (Bromide). This product is intended for research and analytical applications. Rocuronium Bromide (ORG 9426 Bromide) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal musclerelaxation during surgery or mechanical ventilation.
    Rocuronium Bromide (Standard)
  • HY-17447B
    (1S,2R)-Tranylcypromine hydrochloride 4548-34-9 98%
    (1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1.
    (1S,2R)-Tranylcypromine hydrochloride
  • HY-17498B
    Atenolol hydrochloride 51706-40-2 98%
    Atenolol hydrochloride is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol hydrochloride can be used for the research of hypertension and angina pectoris.
    Atenolol hydrochloride
  • HY-17552R
    sn-Glycero-3-phosphocholine (Standard) 28319-77-9
    sn-Glycero-3-phosphocholine (Standard) is the analytical standard of sn-Glycero-3-phosphocholine. This product is intended for research and analytical applications. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
    sn-Glycero-3-phosphocholine (Standard)
  • HY-17555A
    Meclofenoxate 51-68-3
    Meclofenoxate (Centrophenoxine) is an ester synthesized from DMAE and pCPA, which has the activity of stimulating memory and improving cognition.
    Meclofenoxate
  • HY-176012
    1S-LSD 98%
    1S-LSD is a lysergic acid diethylamide (LSD) analog and a psychotropic substance.
    1S-LSD
  • HY-176040
    IXA62 956783-34-9 98%
    IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells.
    IXA62
  • HY-176049
    Dasatinib derivative 1 3079237-53-6 98%
    Dasatinib derivative 1 (2e) effectively releases NO and increases the concentration of 3′,5′-cyclic guanosine monophosphate, as well as maintains senolytic activity. Dasatinib derivative 1 (2e) can be used in the research for chronic ocular hypertension (COHT) glaucoma.
    Dasatinib derivative 1
Cat. No. Product Name / Synonyms Application Reactivity